Development and validation of a novel bleeding risk score during direct oral anticoagulant therapy in patients with cancer-associated venous thromboembolism
Patients with cancer-associated venous thromboembolism (VTE) are at high risk of major bleeding during anticoagulant therapy, underscoring the need for accurate bleeding risk assessment in the era of direct oral anticoagulants (DOACs). However, few bleeding risk scores have been specifically developed and validat...